{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:22:18Z","timestamp":1787595738036,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-025-00530-x","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T07:31:59Z","timestamp":1753083119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and patient-reported impact of on-flare retreatment in patients with rheumatoid arthritis: insights from retrospective long-term real-world data"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4330-1447","authenticated-orcid":false,"given":"Delphine","family":"Bertrand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"De Meyst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Doumen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik","family":"De Cock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Neerinckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Pazmino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Pype","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Conings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Westhovens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Verschueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"1","key":"530_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"530_CR2","first-page":"Cd007848","volume":"2009","author":"JA Singh","year":"2009","unstructured":"Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009;2009(4):Cd007848.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"530_CR3","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793\u2013806.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"530_CR4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"530_CR5","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s10067-015-2977-z","volume":"34","author":"M Bredemeier","year":"2015","unstructured":"Bredemeier M, Campos GG, de Oliveira FK. Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis. Clin Rheumatol. 2015;34(10):1801\u20135.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"530_CR6","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1016\/S2665-9913(19)30066-9","volume":"1","author":"LM Verhoef","year":"2019","unstructured":"Verhoef LM, den Broeder N, Thurlings RM, van der Laan WH, van der Weele W, Kok MR, et al. Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial. Lancet Rheumatol. 2019;1(3):e145\u201353.","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"530_CR7","doi-asserted-by":"publisher","first-page":"R169","DOI":"10.1186\/ar3129","volume":"12","author":"B Vander Cruyssen","year":"2010","unstructured":"Vander Cruyssen B, Durez P, Westhovens R, Kaiser MJ, Hoffman I, De Keyser F, et al. The Belgian MIRA (MabThera in rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies. Arthritis Res Ther. 2010;12(5):R169.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"530_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/rheumatology\/keab248","volume":"61","author":"C Norris-Grey","year":"2022","unstructured":"Norris-Grey C, Cambridge G, Moore S, Reddy V, Leandro M. Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020. Rheumatology (Oxford). 2022;61(2):591\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"530_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3899\/jrheum.160460","volume":"44","author":"K Chatzidionysiou","year":"2017","unstructured":"Chatzidionysiou K, Lie E, Lukina G, Hetland ML, Hauge EM, Pavelka K, et al. Rituximab retreatment in rheumatoid arthritis in a Real-life cohort: data from the CERERRA collaboration. J Rheumatol. 2017;44(2):162\u20139.","journal-title":"J Rheumatol"},{"issue":"6","key":"530_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1136\/ard.2008.100438","volume":"68","author":"YK Teng","year":"2009","unstructured":"Teng YK, Tekstra J, Breedveld FC, Lafeber F, Bijlsma JW, van Laar JM. Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies. Ann Rheum Dis. 2009;68(6):1075\u20137.","journal-title":"Ann Rheum Dis"},{"key":"530_CR11","doi-asserted-by":"crossref","unstructured":"Schapink L, den Broeder N, den Broeder AA, Verhoef LM. Treat-to-target vs fixed interval retreatment strategy with rituximab in rheumatoid arthritis: A retrospective cohort study. Rheumatol Int. 2024.","DOI":"10.1007\/s00296-023-05524-x"},{"key":"530_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","volume":"1","author":"B Bruce","year":"2003","unstructured":"Bruce B, Fries JF. The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1:20.","journal-title":"Health Qual Life Outcomes"},{"issue":"Suppl 11","key":"530_CR13","first-page":"S14","volume":"63","author":"JK Anderson","year":"2011","unstructured":"Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: patient (PtGA) and provider (PrGA) global assessment of disease activity, disease activity score (DAS) and disease activity score with 28-Joint counts (DAS28), simplified disease activity index (SDAI), clinical disease activity index (CDAI), patient activity score (PAS) and patient activity score-II (PASII), routine assessment of patient index data (RAPID), rheumatoid arthritis disease activity index (RADAI) and rheumatoid arthritis disease activity index-5 (RADAI-5), chronic arthritis systemic index (CASI), patient-Based disease activity score with ESR (PDAS1) and patient-Based disease activity score without ESR (PDAS2), and mean overall index for rheumatoid arthritis (MOI-RA). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S14\u201336.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"530_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","volume":"42","author":"JS Smolen","year":"2003","unstructured":"Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42(2):244\u201357.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"530_CR15","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"530_CR16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/rheumatology\/key036","volume":"57","author":"AGS Oldroyd","year":"2018","unstructured":"Oldroyd AGS, Symmons DPM, Sergeant JC, Kearsley-Fleet L, Watson K, Lunt M, et al. Long-term persistence with rituximab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2018;57(6):1089\u201396.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"530_CR17","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.131279","volume":"41","author":"F De Keyser","year":"2014","unstructured":"De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in rheumatoid arthritis registry. J Rheumatol. 2014;41(9):1761\u20135.","journal-title":"J Rheumatol"},{"issue":"8","key":"530_CR18","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","volume":"56","author":"MY Md Yusof","year":"2017","unstructured":"Md Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years\u2019 experience at a single centre. Rheumatology (Oxford). 2017;56(8):1348\u201357.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"530_CR19","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","volume":"76","author":"C Hyldgaard","year":"2017","unstructured":"Hyldgaard C, Hilberg O, Pedersen AB, Ulrichsen SP, L\u00f8kke A, Bendstrup E, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76(10):1700\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"530_CR20","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1093\/rheumatology\/keaa836","volume":"60","author":"JA Sparks","year":"2021","unstructured":"Sparks JA, Jin Y, Cho SK, Vine S, Desai R, Doyle TJ, et al. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatology (Oxford). 2021;60(8):3689\u201398.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"530_CR21","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"E Keystone","year":"2007","unstructured":"Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896\u2013908.","journal-title":"Arthritis Rheum"},{"key":"530_CR22","doi-asserted-by":"publisher","first-page":"1759720X2412322","DOI":"10.1177\/1759720X241232268","volume":"16","author":"D Bertrand","year":"2024","unstructured":"Bertrand D, Deprez A, Doumen M, De Cock D, Pazmino S, Marchal A, et al. To flare or not to flare: patients\u2019 and rheumatologists\u2019 perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2024;16:1759720X241232268.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"530_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/03009742.2013.765030","volume":"42","author":"N van Herwaarden","year":"2013","unstructured":"van Herwaarden N, van der Maas A, Jansen TL, Dutmer EA, Hartkamp A, van Riel PL, et al. Can response duration after the first rituximab treatment be used in timing of rituximab retreatment? Scand J Rheumatol. 2013;42(3):251\u20132.","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"530_CR24","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/rheumatology\/kead326","volume":"63","author":"MAA Opdam","year":"2024","unstructured":"Opdam MAA, Campisi LM, de Leijer JH, Ten Cate D, den Broeder AA. Hypogammaglobulinemia in rheumatoid arthritis patients on rituximab: prevalence and risk factors. Rheumatology (Oxford). 2024;63(1):e1\u20132.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"530_CR25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/art.41938","volume":"74","author":"G Evangelatos","year":"2022","unstructured":"Evangelatos G, Moschopoulou M, Iliopoulos A, Fragoulis GE. Hypogammaglobulinemia in rheumatoid arthritis patients treated with rituximab: should we switch biologics? Comment on the Article by Fraenkel et al. Arthritis Rheumatol. 2022;74(1):174\u20135.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"530_CR26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/rheumatology\/keac318","volume":"62","author":"MAA Opdam","year":"2022","unstructured":"Opdam MAA, de Leijer JH, den Broeder N, Thurlings RM, van der Weele W, Nurmohamed MT, et al. Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through Circulating immunoglobulins, neutrophils or B cells. Rheumatology (Oxford). 2022;62(1):330\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"530_CR27","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1002\/art.23902","volume":"58","author":"S Dass","year":"2008","unstructured":"Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2993\u20139.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"530_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/art.30152","volume":"63","author":"EM Vital","year":"2011","unstructured":"Vital EM, Rawstron AC, Dass S, Henshaw K, Madden J, Emery P, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603\u20138.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"530_CR29","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1093\/rheumatology\/keac024","volume":"61","author":"MHM Wientjes","year":"2022","unstructured":"Wientjes MHM, Gijzen TMG, den Broeder N, Bloem K, de Vries A, van den Bemt BJF, et al. Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on (ultra-)low-dose rituximab. Rheumatology (Oxford). 2022;61(10):3974\u201380.","journal-title":"Rheumatology (Oxford)"},{"key":"530_CR30","doi-asserted-by":"crossref","unstructured":"Ghossan R, Al Tabaa O, Combier A, Steelandt A, Thomas M, Fogel O et al. Should complete B-cell depletion be maintained in patients treated long-term with rituximab for rheumatoid arthritis? Rheumatology (Oxford). 2023.","DOI":"10.1093\/rheumatology\/kead528"},{"key":"530_CR31","unstructured":"European Medicines Agency, Annex I. Summary of product characteristics MabThera [April 26, 2024]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_en.pdf"},{"issue":"3","key":"530_CR32","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/rheumatology\/kex446","volume":"57","author":"J Henry","year":"2018","unstructured":"Henry J, Gottenberg JE, Rouanet S, Pavy S, Sellam J, Tubach F, et al. Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection. Rheumatology (Oxford). 2018;57(3):538\u201347.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"530_CR33","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/annrheumdis-2013-204920","volume":"74","author":"R Fleischmann","year":"2015","unstructured":"Fleischmann R, van der Heijde D, Koenig AS, Pedersen R, Szumski A, Marshall L, et al. How much does disease activity score in 28 joints ESR and CRP calculations underestimate disease activity compared with the simplified disease activity index? Ann Rheum Dis. 2015;74(6):1132\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"530_CR34","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","volume":"3","author":"J Avouac","year":"2021","unstructured":"Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3(6):e419\u201326.","journal-title":"Lancet Rheumatol"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00530-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00530-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00530-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:15:17Z","timestamp":1757261717000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00530-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["530"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00530-x","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the University Hospitals of Leuven granted approval of this study (internal reference number: S63417). Due to the retrospective character of the study, no informed consent forms were required and obtained (Belgian Law of 7 May 2004 on experiments with human subjects).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}